Tenaya Therapeutics (TNYA) Change in Accured Expenses (2020 - 2026)

Tenaya Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$2.6 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 38.57% year-over-year to -$2.6 million in Q1 2026; TTM through Mar 2026 was -$202000.0, a 91.21% increase from a year earlier, with the FY2025 full-year figure at $532000.0, up 111.21% from the prior year.
• Change in Accured Expenses declined to -$2.6 million in Q1 2026 per TNYA's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.6 million in Q4 2023 and bottomed at -$4.4 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $596000.0 (2024), against an average of -$14470.6.
• Biggest YoY gain for Change in Accured Expenses was 184.99% in 2023; the steepest drop was 937.11% in 2023.
• Year by year, Change in Accured Expenses stood at $2.3 million in 2022, then advanced by 11.28% to $2.6 million in 2023, then plunged by 72.3% to $708000.0 in 2024, then soared by 59.04% to $1.1 million in 2025, then plunged by 334.19% to -$2.6 million in 2026.
• Per Business Quant, the three latest TNYA Change in Accured Expenses figures stand at -$2.6 million (Q1 2026), $1.1 million (Q4 2025), and $918000.0 (Q3 2025).